Drugs Containing Excipient (Inactive Ingredient) GLYCERYL DIOLEATE

« Back to Dashboard

Branded drugs containing GLYCERYL DIOLEATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Braeburn Inc	BRIXADI	buprenorphine	58284-208	GLYCERYL DIOLEATE

Generic drugs containing GLYCERYL DIOLEATE excipient

Company	Ingredient	NDC	Excipient
Braeburn Inc	buprenorphine	58284-208	GLYCERYL DIOLEATE

Glyceryl Dioleate Market Dynamics, Pharmaceutical Applications, and Financial Trajectory

Last updated: October 19, 2026

Glyceryl dioleate is a specialty lipid excipient used mainly in oral lipid-based drug-delivery systems, emulsions, solubilizing systems, and modified-release formulations. Its commercial market is small relative to mainstream excipients such as lactose, microcrystalline cellulose, magnesium stearate, polysorbates, and polyethylene glycols. Public companies do not generally report glyceryl dioleate revenue separately, so the financial trajectory must be assessed through formulation demand, specialty-lipid pricing, supplier capacity, regulatory qualification, and customer concentration.

The market outlook is positive but narrow. Growth depends more on pharmaceutical formulation adoption than on volume expansion across the broader excipient sector. The strongest demand is likely to come from poorly water-soluble drugs, lipid-based oral delivery, long-acting lipid systems, and development-stage products that require enhanced solubilization or controlled release.

What is glyceryl dioleate and how is it used in pharmaceuticals?

Glyceryl dioleate, also called glycerol dioleate or diolein, is a glyceride formed from glycerol and two oleic acid residues. It is a nonionic, oil-soluble lipid with amphiphilic behavior. Commercial material may contain positional isomers and related mono- and triglycerides, depending on the manufacturing route and specification.

Its pharmaceutical value comes from four functions:

1. Solubilization of lipophilic active pharmaceutical ingredients.
2. Formation of lipid matrices and self-emulsifying delivery systems.
3. Modulation of drug release through lipid digestion or matrix erosion.
4. Improvement of wetting, dispersion, and interfacial behavior in oral dosage forms.

Glyceryl dioleate is most relevant to drugs with low aqueous solubility. Lipid-based formulations can promote drug absorption by maintaining the active ingredient in a solubilized state after oral administration. The approach is established in pharmaceutical development, although the excipient itself is not a universal substitute for more widely qualified lipids such as medium-chain triglycerides, long-chain triglycerides, glyceryl monooleate, phospholipids, polysorbates, or surfactant blends.

Which dosage forms use glyceryl dioleate?

The most commercially relevant dosage forms are:

Dosage form	Potential role of glyceryl dioleate	Commercial relevance
Soft gelatin capsules	Lipid vehicle, solubilizer, matrix component	High
Hard capsules with liquid or semisolid fill	Lipid carrier or dispersion component	Moderate
Self-emulsifying drug-delivery systems	Oil-phase component	High in development programs
Nanoemulsions and emulsions	Interfacial and lipid-phase component	Moderate
Sustained-release oral systems	Hydrophobic matrix former	Moderate
Topical and transdermal systems	Emollient or penetration-modifying lipid	Limited to moderate
Parenteral products	Specialized lipid component	Low because of purity and safety requirements

The strongest fit is oral delivery. Parenteral use faces higher requirements for endotoxins, particulate control, oxidation, sterilization compatibility, and route-specific toxicology.

How large is the glyceryl dioleate market?

No authoritative public source reports a standalone global market size for pharmaceutical-grade glyceryl dioleate. Market research companies generally group it within specialty excipients, oleochemicals, lipid excipients, or pharmaceutical formulation ingredients.

This reporting structure has three consequences:

• Supplier revenue cannot be isolated reliably.
• Published market estimates may combine pharmaceutical, nutraceutical, cosmetic, food, and industrial grades.
• Volume growth and value growth can diverge because pharmaceutical-grade material commands a higher price than technical or cosmetic grades.

The relevant addressable market is therefore the pharmaceutical-grade segment rather than total glyceryl dioleate production. Pharmaceutical demand is likely measured in specialty-lipid volumes, formulation-development batches, and recurring commercial supply contracts rather than large commodity tonnage.

What drives demand for glyceryl dioleate?

Demand is influenced by five structural factors:

• Rising development activity for poorly soluble small-molecule drugs.
• Use of lipid-based formulations to improve oral bioavailability.
• Growth in self-emulsifying and self-microemulsifying drug-delivery systems.
• Increased use of multifunctional excipients that combine solubilization and release control.
• Demand for nonionic, biodegradable lipid materials with established pharmaceutical handling properties.

The primary limitation is substitution. Formulators can often replace glyceryl dioleate with glyceryl monooleate, oleic acid, medium-chain triglycerides, long-chain triglycerides, phosphatidylcholine, polysorbates, poloxamers, or proprietary lipid blends. A supplier therefore needs consistent performance and regulatory documentation, not merely chemical availability.

What is the financial trajectory for glyceryl dioleate?

The financial trajectory is best characterized as low-volume, specialty-margin growth rather than commodity-scale expansion.

Revenue profile

Pharmaceutical-grade glyceryl dioleate revenue typically develops in stages:

Stage	Revenue characteristics	Margin profile
Discovery and formulation screening	Small laboratory orders	High technical value, low absolute revenue
Preclinical and clinical development	Repeated kilogram-scale purchases	Improving revenue visibility
Registration and validation	Qualification batches and audits	High switching costs
Commercial launch	Recurring supply under specifications	Strongest revenue quality
Mature product supply	Stable annual volumes	Pricing pressure increases over time

The major financial inflection occurs when an excipient is incorporated into a registered product. A single commercial drug can create more durable revenue than many early-stage formulation projects. Before that point, sales remain exposed to clinical failure, formulation changes, and substitution.

Pricing and margin factors

Pricing is driven by:

• Purity and assay specifications.
• Low peroxide and oxidation limits.
• Residual solvent and heavy-metal controls.
• Batch-to-batch composition.
• GMP manufacturing and documentation.
• Packaging and storage requirements.
• Regulatory support.
• Minimum order quantities.
• Customer-specific qualification.

Pharmaceutical-grade material can carry a substantial premium over industrial or cosmetic grades, but the premium is not guaranteed. Buyers with validated formulations can negotiate aggressively once multiple suppliers qualify.

The commercial value lies less in the raw lipid and more in the complete supply package: controlled composition, stability data, analytical methods, change-control procedures, audit support, and regulatory documentation.

Which companies supply or compete with glyceryl dioleate?

The competitive landscape includes oleochemical manufacturers, specialty-excipient suppliers, lipid-formulation companies, and distributors. Public disclosure does not establish that every major oleochemical company sells pharmaceutical-grade glyceryl dioleate as a standard catalog product.

Relevant competitor groups include:

Specialty lipid and excipient suppliers

Companies active in related pharmaceutical lipids include Gattefossé, Croda, IOI Oleo, ABITEC, BASF, Evonik, and Kerry. Their competitive position is often based on broader lipid portfolios rather than glyceryl dioleate alone.

Gattefossé competes through lipid excipients and formulation-development expertise. Croda and IOI Oleo participate in pharmaceutical and specialty oleochemical supply. ABITEC has a portfolio of lipid excipients and formulation ingredients. BASF and Evonik compete more broadly in excipients, solubilizers, polymers, and drug-delivery technologies.

Substitution pressure

The most direct substitutes are:

• Glyceryl monooleate.
• Glyceryl monostearate.
• Medium-chain triglycerides.
• Long-chain triglycerides.
• Oleic acid.
• Phosphatidylcholine.
• Polysorbates.
• Poloxamers.
• PEG-based lipid excipients.
• Proprietary self-emulsifying excipient systems.

Glyceryl monooleate may have a stronger pharmaceutical identity in some formulation applications because of its established use in liquid-crystalline and sustained-release systems. Glyceryl dioleate can compete where a more unsaturated, oil-like lipid profile is preferred.

What regulatory status does glyceryl dioleate have?

Glyceryl dioleate is an excipient rather than an active pharmaceutical ingredient. Its regulatory position depends on route, dosage form, concentration, source, purity, and prior human exposure.

The U.S. Food and Drug Administration’s Inactive Ingredient Database is the principal public reference for excipient precedent in approved drug products. Presence in the database does not constitute blanket approval for every route or concentration. Developers must confirm the exact substance name, route, dosage form, maximum potency, and regulatory context in the current database. FDA states that the database is used to identify inactive ingredients previously used in approved drug products and to support certain regulatory assessments (U.S. Food and Drug Administration, n.d.-a).

What is the FDA Orange Book status of glyceryl dioleate?

Glyceryl dioleate has no standalone Orange Book exclusivity because the Orange Book covers approved drug products and their associated active-ingredient patents and exclusivities, not excipient molecules as independent products. The relevant Orange Book question is whether a finished drug containing glyceryl dioleate has listed patents or regulatory exclusivity.

An excipient supplier therefore does not receive Orange Book protection merely by selling glyceryl dioleate. Protection can arise indirectly through:

• Patents covering a drug formulation containing glyceryl dioleate.
• Patents covering a specific lipid ratio or composition.
• Method-of-use patents covering administration of a drug in the formulation.
• Manufacturing patents covering a specialized grade or process.
• Trade secrets involving purification, stabilization, or composition control.

What patents protect glyceryl dioleate formulations?

The core chemical structure of glyceryl dioleate is old and is unlikely to provide a meaningful new-molecule patent position. Commercial protection is more likely to concern formulation architecture.

Formulation patents

Potentially protectable subject matter includes:

• A defined ratio of glyceryl dioleate to active ingredient.
• A self-emulsifying system with a specified surfactant and co-solvent.
• A lipid matrix that produces a defined dissolution profile.
• A composition that improves exposure to a particular drug.
• A capsule fill with specified viscosity, stability, or precipitation characteristics.
• A nanoparticle, emulsion, or liquid-crystalline delivery system.

Method-of-use patents

Method claims may cover treatment of a disease using a drug administered in a glyceryl-dioleate-containing formulation. These patents are usually tied to the active pharmaceutical ingredient and clinical effect, not to glyceryl dioleate itself.

Manufacturing and quality patents

Manufacturing protection may cover:

• Selective enrichment of the dioleate fraction.
• Removal of oxidation products.
• Control of positional isomers.
• Low-peroxide production.
• Stabilization against hydrolysis or oxidation.
• Pharmaceutical-grade purification and packaging.

Such rights can create supply barriers, but they rarely prevent all competitors from producing a chemically equivalent material.

Are there Paragraph IV challenges involving glyceryl dioleate?

There are no standalone Paragraph IV challenges directed to glyceryl dioleate as an excipient. Paragraph IV litigation applies to abbreviated new drug applications that challenge patents listed for a reference listed drug under the Hatch-Waxman framework.

A generic applicant may challenge formulation patents that claim a finished drug containing glyceryl dioleate. The dispute would center on the listed drug, patent scope, infringement, validity, and regulatory certification. The excipient itself would not usually be the target.

What litigation and settlement risks affect glyceryl dioleate suppliers?

Supplier-specific litigation risk is generally lower than sponsor-specific formulation litigation risk. The principal disputes are likely to involve:

• Patent infringement by generic drug applicants.
• Formulation ownership between drug sponsors and contract developers.
• Supply agreements and change-control obligations.
• Batch failures or out-of-specification material.
• Mislabeling of pharmaceutical versus cosmetic grade.
• Confidentiality and trade-secret claims.
• Regulatory consequences of changing the source or composition.

Settlement agreements may restrict generic launch dates, manufacturing sources, or formulation changes when a drug patent is challenged. Those agreements concern the finished pharmaceutical product and generally do not create broad exclusivity for glyceryl dioleate suppliers.

What manufacturing barriers affect the market?

The main barriers are quality consistency and regulatory qualification, not basic chemical synthesis.

Glyceryl dioleate can be produced through esterification, glycerolysis, or fractionation of glyceride mixtures. Pharmaceutical customers require tighter control over composition than nonpharmaceutical buyers. Relevant quality attributes include:

• Fatty-acid composition.
• Mono-, di-, and triglyceride distribution.
• Positional isomer profile.
• Acid value.
• Peroxide value.
• Water content.
• Residual solvents.
• Elemental impurities.
• Microbial quality.
• Oxidative and hydrolytic stability.

A supplier may also need to demonstrate compatibility with gelatin shells, capsule seals, oxygen exposure, filling temperatures, and long-term storage.

The qualification cycle can be lengthy because changing the lipid source or manufacturing site may require comparability data, stability studies, regulatory notification, or customer revalidation. This creates moderate switching costs after commercial approval.

How does glyceryl dioleate compare with glyceryl monooleate?

Attribute	Glyceryl dioleate	Glyceryl monooleate
Molecular composition	Two oleic acid residues	One oleic acid residue
Physical character	More oil-like and hydrophobic	More amphiphilic and structured
Main formulation role	Lipid vehicle, solubilizer, matrix component	Emulsifier, liquid-crystalline former, matrix component
Pharmaceutical adoption	Niche	Broader in certain delivery systems
Substitution risk	Moderate to high	Moderate
Key development issue	Composition and oxidation control	Polymorphism and phase behavior
Commercial positioning	Specialty lipid	Established lipid excipient category

The choice depends on drug logP, dose, precipitation risk, digestion behavior, capsule compatibility, and desired release profile. Neither material is universally superior.

What generic launch risks exist for products using glyceryl dioleate?

Generic-entry risk depends on the finished drug’s patent estate, not on the excipient alone. Risk is higher when:

• The formulation patent claims broad lipid classes.
• Glyceryl dioleate is required for a defined pharmacokinetic effect.
• The Orange Book contains multiple formulation or method patents.
• The dosage form is difficult to reproduce.
• The reference product depends on a narrow lipid ratio.
• The generic must conduct extensive bioequivalence work.

Risk is lower when glyceryl dioleate is an optional excipient and the generic can use a different lipid vehicle without infringing claims or changing bioequivalence performance.

What is the geographic outlook for glyceryl dioleate?

North America and Europe remain important for regulated pharmaceutical-grade supply, excipient qualification, and commercial drug development. Asia-Pacific is likely to record the strongest growth in formulation activity because of expanding generic manufacturing, contract development, pharmaceutical exports, and domestic drug production.

Geographic risks include:

• Different excipient nomenclature and monograph treatment.
• Local GMP expectations.
• Import controls for animal- or vegetable-derived materials.
• Country-specific registration requirements.
• Supply-chain concentration in oleochemical feedstocks.
• Different acceptance of noncompendial excipients.

A global supplier must maintain documentation suitable for FDA, European, Japanese, and other national regulatory submissions. Regional substitution may be possible, but changing sources after approval can trigger comparability work.

What licensing deals involve glyceryl dioleate?

Public licensing disclosures specifically naming glyceryl dioleate are limited. Licensing activity is more commonly structured around:

• Drug-delivery platforms.
• Self-emulsifying formulations.
• Nanoparticle or lipidic delivery systems.
• Finished drug products.
• Contract development and manufacturing arrangements.

The excipient may appear in confidential formulation packages without being named in public transaction announcements. Suppliers gain commercial leverage when their grade is embedded in a licensed formulation, but the intellectual-property value normally belongs to the formulation owner rather than the raw-material supplier.

Key Takeaways

• Glyceryl dioleate is a niche pharmaceutical lipid excipient with its strongest use in oral lipid-based delivery systems.
• No reliable public standalone market-size series exists for pharmaceutical-grade glyceryl dioleate.
• Financial growth depends on formulation adoption and commercial drug launches, not broad commodity volume.
• The main substitutes are glyceryl monooleate, triglycerides, phospholipids, oleic acid, polysorbates, poloxamers, and proprietary lipid systems.
• Regulatory value comes from documented pharmaceutical use, controlled specifications, and supplier qualification.
• Glyceryl dioleate has no independent Orange Book exclusivity and is not the subject of standalone Paragraph IV litigation.
• The strongest patent opportunities concern formulations, release profiles, methods of use, and specialized manufacturing processes.
• Manufacturing barriers are based on composition control, oxidation stability, GMP documentation, and change-control requirements.
• The commercial opportunity is attractive for qualified specialty suppliers but limited by substitution and customer concentration.

FAQs About Glyceryl Dioleate in Pharmaceutical Markets

Is glyceryl dioleate the same as diolein?

Yes. Glyceryl dioleate is commonly referred to as diolein or glycerol dioleate. Commercial specifications can vary in isomer distribution and related glyceride content.

Can glyceryl dioleate be used in softgel capsules?

Yes. It can function as an oil-phase carrier, solubilizer, or lipid matrix component in softgel formulations, subject to compatibility, stability, and regulatory qualification.

Is glyceryl dioleate a high-volume pharmaceutical excipient?

No. It is a specialty excipient. Its pharmaceutical volume is materially smaller than that of lactose, microcrystalline cellulose, magnesium stearate, polyethylene glycols, or common surfactants.

Does glyceryl dioleate have a Drug Master File?

A supplier may maintain a Drug Master File or equivalent confidential regulatory package, but the existence and scope of a specific filing are supplier-dependent and are not generally visible from the excipient’s chemical identity alone.

Can a generic drug replace glyceryl dioleate with another lipid?

Potentially. The change depends on formulation patent scope, bioequivalence performance, product quality, regulatory requirements, and whether glyceryl dioleate is essential to the reference product’s release or absorption profile.

References

European Medicines Agency. (2013). Guideline on the assessment of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract. https://www.ema.europa.eu/

U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptides, guidance for industry. https://www.fda.gov/

U.S. Pharmacopeia. (2023). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. Council of Europe.